UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 23, 2022
(Date of earliest event reported)
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices, and Zip Code)
(858 ) 362-6295
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 23, 2022, AnaptysBio, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders and the following proposals were adopted:
1.Election of three Class II directors, Laura J. Hamill, James Topper, M.D., Ph.D., and J. Anthony Ware, M.D., each to serve a three-year term, which will expire at the 2025 Annual Meeting of Stockholders or until such time as his or her respective successor have been duly elected and qualified or until such director’s earlier resignation or removal:
| Nominees | Shares For | Shares Withheld / Abstaining | Broker Non-Votes | |||||||||||||||||
| Laura J. Hamill | 18,530,964 | 3,884,104 | 2,986,393 | |||||||||||||||||
| James Topper, M.D., Ph.D. | 18,338,960 | 4,076,108 | 2,986,393 | |||||||||||||||||
| J. Anthony Ware, M.D. | 18,397,904 | 4,017,164 | 2,986,393 | |||||||||||||||||
2.Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022:
| Shares For | Shares Against | Shares Withheld/Abstaining | Broker Non-Votes | |||||||||||||||||
| 25,369,483 | 30,540 | 1,438 | — | |||||||||||||||||
3.Non-binding, advisory approval of compensation paid to the Company’s named executive officers:
| Shares For | Shares Against | Shares Withheld/Abstaining | Broker Non-Votes | |||||||||||||||||
| 21,241,128 | 1,166,695 | 7,245 | 2,986,393 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AnaptysBio, Inc. | |||||||||||
| Date: June 24, 2022 | By: | /s/ Eric Loumeau | |||||||||
Name: Eric Loumeau | |||||||||||
Title: Chief Operating Officer and General Counsel | |||||||||||